Stay updated on Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedThe record history now includes a new revision entry, v3.5.4, while the previous v3.5.3 entry is removed from the list.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe record history now shows a new revision (v3.5.3) replacing the previous v3.5.2. It represents an update to the study record in the history log.SummaryDifference0.0%

- Check48 days agoChange DetectedAdded Revision: v3.5.2 to the history and removed Revision: v3.5.0.SummaryDifference0.0%

- Check77 days agoChange DetectedNew revision entry v3.5.0 added to the history. The v3.4.3 entry was removed.SummaryDifference0.0%

- Check84 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check91 days agoChange DetectedThe trial status is updated to Terminated with primary results showing no benefit from canakinumab. The previous Active, not recruiting status has been removed.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.